dequalinium Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4376 | 6707-58-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A topical bacteriostat that is available as various salts. It is used in wound dressings and mouth infections and may also have antifungal action, but may cause skin ulceration.
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 20 | mg | V |
| 1.50 | mg | O |
ADMET properties:
None
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Inflammatory marker increased | 94.96 | 59.48 | 19 | 394 | 5456 | 46680193 |
| Irritable bowel syndrome | 74.07 | 59.48 | 19 | 394 | 16496 | 46669153 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D08AH01 | DERMATOLOGICALS ANTISEPTICS AND DISINFECTANTS ANTISEPTICS AND DISINFECTANTS Quinoline derivatives |
| ATC | G01AC05 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Quinoline derivatives |
| ATC | R02AA02 | RESPIRATORY SYSTEM THROAT PREPARATIONS THROAT PREPARATIONS Antiseptics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000891 | Anti-Infective Agents, Local |
| CHEBI has role | CHEBI:35610 | cytostatic |
| CHEBI has role | CHEBI:35718 | antifungal drug |
| CHEBI has role | CHEBI:38498 | mitochondrial complex i inhibitors |
| CHEBI has role | CHEBI:48218 | antiseptics |
Drug Use (View source of the data)
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 4.92 | Basic |
| pKa2 | 4.32 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Small conductance calcium-activated potassium channel protein 1 | Ion channel | BLOCKER | IC50 | 6.40 | IUPHAR | ||||
| Small conductance calcium-activated potassium channel protein 3 | Ion channel | IC50 | 5.89 | CHEMBL | |||||
| Protein kinase C alpha type | Kinase | IC50 | 4.96 | CHEMBL | |||||
| cGMP-gated cation channel alpha-1 | Unclassified | BLOCKER | IC50 | 6.70 | IUPHAR | ||||
| Cyclic nucleotide-gated olfactory channel | Unclassified | BLOCKER | IC50 | 5.60 | IUPHAR | ||||
| Small conductance calcium-activated potassium channel protein 3 | Ion channel | Ki | 6.85 | CHEMBL | |||||
| Small conductance calcium-activated potassium channel protein 2 | Unclassified | BLOCKER | IC50 | 6.80 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D01575 | KEGG_DRUG |
| N0000166911 | NUI |
| 522-51-0 | SECONDARY_CAS_RN |
| C0011588 | UMLSCUI |
| CHEBI:31466 | CHEBI |
| DEQ | PDB_CHEM_ID |
| CHEMBL333826 | ChEMBL_ID |
| CHEMBL121663 | ChEMBL_ID |
| DB04209 | DRUGBANK_ID |
| D003868 | MESH_DESCRIPTOR_UI |
| 2993 | PUBCHEM_CID |
| 2313 | IUPHAR_LIGAND_ID |
| 746 | INN_ID |
| E7QC7V26B8 | UNII |
| 3120 | RXNORM |
| 003481 | NDDF |
| 004966 | NDDF |
| 350274005 | SNOMEDCT_US |
| 395964006 | SNOMEDCT_US |
| 396013001 | SNOMEDCT_US |
Pharmaceutical products:
None